Recent News

• 05.14.2026 - Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
• 05.07.2026 - Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• 04.15.2026 - Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
• 03.27.2026 - Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
• 03.24.2026 - Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
• 03.12.2026 - Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
• 03.06.2026 - Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Recent Filings

• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 8-K Current report
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.30.2026 - ARS Annual Report to Security Holders
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.30.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2026 - 8-K Current report
• 03.27.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2026 - EX-99.1 EX-99.1